On September 30, 2020, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of new Procedures for CADTH Drug Reimbursement Reviews (updated October 29, 2020), which harmonize procedures under CADTH’s drug reimbursement review pathways (Common Drug Review, pan-Canadian Oncology Drug Review, and Interim Plasma Protein Product Review). Notable highlights include the opportunity for drug manufacturers to comment on draft review reports; posting of draft recommendations for stakeholder feedback; and introduction of categories in the reconsideration process to promote flexibility.